This report marks the midway point of the 1/4/6×24 Campaign, which calls for the universal implementation of the best available TB regimens — as little as one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024. The report takes stock of what 1/4/6×24 has accomplished so far since its founding in 2022, and analyzes remaining gaps to be filled to reach its ambitious goal by the end of this year — particularly pertaining to the “4” regimen, for which uptake has been sorely limited and which original modeling shows has the potential to reduce total treatment time by 6.3 million years through 2030. Read the report here.
top of page
Recent Posts
See AllTheir annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full
100
The Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
410
Calls for strengthening health systems in preparation for the next pandemic have intensified in the wake of COVID-19, with estimates ranging from $15 billion to $50 billion needed annually to scale up
580
bottom of page